Abstract
Meeting abstracts Encouraging data have emerged from adoptive T-cell therapies in advanced forms of cancer. Anti-tumor immunity is found in tumor infiltrating lymphocytes as well as engineered T cells where exogenous expression of a chimeric antigen receptor (CAR) confers cancer recognition on the
Highlights
Encouraging data have emerged from adoptive T-cell therapies in advanced forms of cancer
Anti-tumor immunity is found in tumor infiltrating lymphocytes as well as engineered T cells where exogenous expression of a chimeric antigen receptor (CAR) confers cancer recognition on the cells
Present adoptive immunotherapy methods are restricted to the use of autologous patient T-cells due to the limited persistence of allogeneic T cells and the potential for graft versus host disease (GvHD)
Summary
Encouraging data have emerged from adoptive T-cell therapies in advanced forms of cancer. Treatment of B cells malignancies with anti-CD19 CAR+, TCR-, CD52- allogeneic T cells Cécile Schiffer Mannioui*, Laëtitia Lemaire, Laurent Poirot, Agnes Gouble, Sylvain Arnould, Roman Galetto, Julianne Smith, Andrew Scharenberg
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
